OBIZUR
STN: BL 125512
Proper Name: Antihemophilic Factor (Recombinant), Porcine Sequence
Tradename: OBIZUR
Manufacturer: Baxter Healthcare Corporation
Indication:
- Treatment and control of bleeding episodes in adults with acquired hemophilia A.
Product Information
Supporting Documents
- February 10, 2023 Approval Letter - OBIZUR
- October 8, 2021 Approval Letter - OBIZUR
- Supporting Documents older than three years - OBIZUR
- Approval History, Letters, Reviews, and Related Documents - OBIZUR